Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | THPO | P40225 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyryl-Carnitine SCHEMBL288391 | 1.00 | MEN1 (0.78) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL237454 | 1.00 | MEN1 (0.78) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL28712508 | 0.98 | MEN1 (0.76) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL28900550 | 0.94 | MEN1 (0.70) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL7048157 | 0.91 | MEN1 (0.77) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL288262 | 0.90 | MEN1 (0.89) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL886920 | 0.90 | MEN1 (0.89) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL6469306 | 0.90 | MEN1 (0.76) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL8977796 | 0.89 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL235082 | 0.89 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112986430-B | Method for screening difference markers of Juansan milk powder and Holstein milk powder and application thereof | 中国农业科学院农业质量标准与检测技术研究所 | 2022-09-16 | — | — | CN | claimed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | claimed |
| US-20170199203-A1 | METABOLITE PANEL FOR IMPROVED SCREENING AND DIAGNOSTIC TESTING OF CYSTIC FIBROSIS | MCMASTER UNIVERSITY (CA) | 2017-07-13 | — | — | US | claimed |
| US-8747906-B2 | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2014-06-10 | — | — | US | claimed |
| US-20130309216-A1 | DIETARY SUPPLEMENT ENHANCING THE MUSCULAR ENERGY METABOLISM, COMPRISING AN ALKANOYL CARNITINE AND RIBOSE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-11-21 | — | — | US | claimed |
| US-8207109-B2 | Mixture of propionyl carnitine, coenzyme Q10, nicotinamide, riboflavin and pantothenine acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2012-06-26 | — | — | US | claimed |
| US-20110313040-A1 | ORGANIC NUTRIENT SALTS, METHODS OF PREPARATION AND USES | BELLUS HEALTH INC. (CA) | 2011-12-22 | — | — | US | claimed |
| EP-1940251-B1 | DIETARY SUPPLEMENT ENERGY-PROVIDING TO SKELETAL MUSCLES AND PROTECTING THE CARDIO VASCULAR TRACT | SIGMA TAU IND FARMACEUTI (IT) | 2011-11-30 | — | — | EP | claimed |
| US-8067468-B2 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC | 2011-11-29 | — | — | US | claimed |
| JP-2011524415-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-0983066-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-03-08 | — | — | EP | claimed |
| WO-2000006134-A2 | USE OF L-CARNITINE AND ITS ALKANOYL DERIVATIVES IN THE PREPARATION OF MEDICAMENTS WITH ANTICANCER ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-02-10 | — | — | WO | claimed |
| WO-1999053921-A1 | COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND NADH AND/OR NADPH | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-10-28 | — | — | WO | claimed |
| EP-0951909-A1 | Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof | Sigma-Tau Healthscience S.p.A. (IT) | 1999-10-27 | — | — | EP | claimed |
| WO-1999052517-A2 | COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-21 | — | — | WO | claimed |
| US-RE36331-E | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-05 | — | — | US | claimed |
| EP-0722724-B1 | Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants | SIGMA TAU IND FARMACEUTI (IT) | 1999-03-24 | — | — | EP | claimed |
| WO-1999006039-A1 | COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND LONG-CHAIN ALKANOLS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-02-11 | — | — | WO | claimed |
| WO-1999001126-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-01-14 | — | — | WO | claimed |
| US-5496821-A | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313040-A1 | ORGANIC NUTRIENT SALTS, METHODS OF PREPARATION AND USES | BDNF, OTC, FABP7 | MEN1 2515/4885KMT2A 3011/4885MAPT 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.